Pituitary

, Volume 21, Issue 2, pp 194–202 | Cite as

Silent somatotroph pituitary adenomas: an update

  • Fabienne Langlois
  • Randall Woltjer
  • Justin S. Cetas
  • Maria Fleseriu
Article
  • 249 Downloads

Abstract

Silent growth hormone adenomas (SGHA) are a rare entity of non-functioning pituitary neuroendocrine tumors. Diagnosis is invariably made post-operatively of a tumor immunopositive for GH (and Pit-1 in selected cases) but without clinical acromegaly. Mainly young females are affected, and tumors are often uncovered by investigation for headaches or oligoamenorrhea. Integration of clinical, pathological and biochemical data is required for proper diagnosis. Beside normal IGF-1 levels, a third of SGHAs displays elevated GH levels and some will eventually progress to acromegaly. Almost two-thirds will be mixed GH-prolactin tumors and sparsely-granulated monohormonal GH tumors seems the more aggressive subtype. Recurrence and need for radiation is higher than other non-functioning tumors so close follow-up is warranted.

Keywords

Silent somatotroph Pituitary Neuroendocrine tumors Non-functioning pituitary adenomas Somatotroph adenomas 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no competing interests.

References

  1. 1.
    Molitch ME (2017) Diagnosis and treatment of pituitary adenomas: a review. JAMA 317(5):516–524CrossRefPubMedGoogle Scholar
  2. 2.
    Melmed S (2016) Pituitary medicine from discovery to patient-focused outcomes. J Clin Endocrinol Metab 101(3):769–777CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Chanson P, Raverot G, Castinetti F, Cortet-Rudelli C, Galland F, Salenave S (2015) Management of clinically non-functioning pituitary adenoma. Ann Endocrinol (Paris) 76(3):239–247CrossRefGoogle Scholar
  4. 4.
    Freda PU, Beckers AM, Katznelson L, Molitch ME, Montori VM, Post KD, Vance ML, Endocrine S (2011) Pituitary incidentaloma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 96(4):894–904CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Aghi MK, Chen CC, Fleseriu M, Newman SA, Lucas JW, Kuo JS, Barkhoudarian G, Farrell CJ, Sheehan J, Ziu M, Dunn IF (2016) Congress of neurological surgeons systematic review and evidence-based guidelines on the management of patients with nonfunctioning pituitary adenomas: executive summary. Neurosurgery 79(4):521–523CrossRefPubMedGoogle Scholar
  6. 6.
    Asa SL, Casar-Borota O, Chanson P, Delgrange E, Earls P, Ezzat S, Grossman A, Ikeda H, Inoshita N, Karavitaki N, Korbonits M, Laws ER Jr, Lopes MB, Maartens N, McCutcheon IE, Mete O, Nishioka H, Raverot G, Roncaroli F, Saeger W, Syro LV, Vasiljevic A, Villa C, Wierinckx A, Trouillas J, and the attendees of 14th Meeting of the International Pituitary Pathology Club AFN (2017) From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): an International Pituitary Pathology Club proposal. Endocr Relat Cancer 24(4):C5–C8CrossRefGoogle Scholar
  7. 7.
    Raverot G, Dantony E, Beauvy J, Vasiljevic A, Mikolasek S, Borson-Chazot F, Jouanneau E, Roy P, Trouillas J (2017) Risk of recurrence in pituitary neuroendocrine tumors: a prospective study using a five-tiered classification. J Clin Endocrinol Metab 102(9):3368–3374CrossRefPubMedGoogle Scholar
  8. 8.
    Osamura RY (2017) Pathology of pituitary tumors update: with World Health Organization new classification 2017. AJSP: Rev Rep 22(4):189–195Google Scholar
  9. 9.
    Lopes MBS (2017) The 2017 World Health Organization classification of tumors of the pituitary gland: a summary. Acta Neuropathol 134(4):521–535CrossRefPubMedGoogle Scholar
  10. 10.
    Cooper O, Melmed S (2012) Subclinical hyperfunctioning pituitary adenomas: the silent tumors. Best Pract Res Clin Endocrinol Metab 26(4):447–460CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Chinezu L, Vasiljevic A, Trouillas J, Lapoirie M, Jouanneau E, Raverot G (2017) Silent somatotroph tumour revisited from a study of 80 patients with and without acromegaly and a review of the literature. Eur J Endocrinol 176(2):195–201CrossRefPubMedGoogle Scholar
  12. 12.
    Wade AN, Baccon J, Grady MS, Judy KD, O’Rourke DM, Snyder PJ (2011) Clinically silent somatotroph adenomas are common. Eur J Endocrinol 165(1):39–44CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Langlois F, Lim DST, Varlamov E, Yedinak CG, Cetas JS, McCartney S, Dogan A, Fleseriu M (2017) Clinical profile of silent growth hormone pituitary adenomas; higher recurrence rate compared to silent gonadotroph pituitary tumors, a large single center experience. Endocrine 58(3):528–534CrossRefPubMedGoogle Scholar
  14. 14.
    Trouillas J, Sassolas G, Loras B, Velkeniers B, Raccurt M, Chotard L, Berthezène F, Tourniaire J, Girod C (1991) Somatotrpic adenomas without acromegaly. Pathol-Res Pract 187(8):943–949CrossRefPubMedGoogle Scholar
  15. 15.
    Saeger W, Ludecke DK, Buchfelder M, Fahlbusch R, Quabbe HJ, Petersenn S (2007) Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry. Eur J Endocrinol 156(2):203–216CrossRefPubMedGoogle Scholar
  16. 16.
    Tourniaire J, Trouillas J, Chalendar D, Bonneton-Emptoz A, Goutelle A, Girod C (1985) Somatotropic adenoma manifested by galactorrhea without acromegaly. J Clin Endocrinol Metab 61(3):451–453CrossRefPubMedGoogle Scholar
  17. 17.
    Batisse M, Raverot G, Maqdasy S, Durando X, Sturm N, Montoriol P-F, Kemeny JL, Chazal J, Trouillas J, Tauveron I (2013) Aggressive silent GH pituitary tumor resistant to multiple treatments, including temozolomide. Cancer Invest 31:190–196CrossRefPubMedGoogle Scholar
  18. 18.
    Bengtsson D, Schrøder HD, Andersen M, Maiter D, Berinder K, Feldt Rasmussen U, Rasmussen ÅK, Johannsson G, Hoybye C, van der Lely AJ, Petersson M, Ragnarsson O, Burman P (2015) Long-term outcome and MGMT as a predictive marker in 24 patients with atypical pituitary adenomas and pituitary carcinomas given treatment with temozolomide. J Clin Endocrinol Metab 100(4):1689–1698CrossRefPubMedGoogle Scholar
  19. 19.
    Daems T, Verhelst J, Michotte A, Abrams P, Ridder D, Abs R (2009) Modification of hormonal secretion in clinically silent pituitary adenomas. Pituitary 12(1):80–86CrossRefPubMedGoogle Scholar
  20. 20.
    Erickson D, Scheithauer B, Atkinson J, Horvath E, Kovacs K, Lloyd RV, Young WF Jr (2009) Silent subtype 3 pituitary adenoma: a clinicopathologic analysis of the Mayo Clinic experience. Clin Endocrinol (Oxford) 71(1):92–99CrossRefGoogle Scholar
  21. 21.
    Furuhata S, Kameya T, Otani M, Shimamoto Y, Asada H, Toya S (1991) Silent mixed growth hormone cell-prolactin cell pituitary adenoma. Endocr Pathol 2(4):230CrossRefGoogle Scholar
  22. 22.
    Fusco A, Giampietro A, Bianchi A, Cimino V, Lugli F, Piacentini S, Lorusso M, Tofani A, Perotti G, Lauriola L, Anile C, Maira G, Pontecorvi A, De Marinis L (2012) Treatment with octreotide LAR in clinically non-functioning pituitary adenoma: results from a case-control study. Pituitary 15(4):571–578CrossRefPubMedGoogle Scholar
  23. 23.
    Ghazi AA, Rotondo F, Kovacs K, Amirbaigloo A, Syro LV, Fathalla H, Di Ieva A, Cusimano MD (2015) Treatment of invasive silent somatotroph pituitary adenoma with temozolomide. Report of a case and review of the literature. Endocr Pathol 26(2):135–139CrossRefPubMedGoogle Scholar
  24. 24.
    Horvath E, Kovacs K, Smyth HS, Cusimano M, Singer W (2005) Silent adenoma subtype 3 of the pituitary—immunohistochemical and ultrastructural classification: a review of 29 cases. Ultrastruct Pathol 29(6):511–524CrossRefPubMedGoogle Scholar
  25. 25.
    Kalavalapalli S, Reid H, Kane J, Buckler H, Trainer P, Heald AH (2007) Silent growth hormone secreting pituitary adenomas: IGF-1 is not sufficient to exclude growth hormone excess. Ann Clin Biochem 44(1):89–93CrossRefPubMedGoogle Scholar
  26. 26.
    Kobayashi I, Oka H, Naritaka H, Sato Y, Fujii K, Kameya T (2002) Expression of Pit-1 and growth hormone-releasing hormone receptor mRNA in human pituitary adenomas: difference among functioning, silent, and other nonfunctioning adenomas. Endocr Pathol 13(2):83–98CrossRefPubMedGoogle Scholar
  27. 27.
    Naritaka H, Kameya T, Sato Y, Furuhata S, Otani M, Kawase T (1999) Morphological characterization and subtyping of silent somatotroph adenomas. Pituitary 1(3):233–241CrossRefPubMedGoogle Scholar
  28. 28.
    Neto L, Chimelli L, Da M. Pereira P, Gasparetto E, Bines J, Wildemberg L, Gadelha M (2013) The role of temozolomide in the treatment of a patient with a pure silent pituitary somatotroph carcinoma. Endocr Pract 19(6):e145–e149CrossRefGoogle Scholar
  29. 29.
    Pestell R, Herington A, Best J, Boolell M, McKelvie P, Arnott R, Alford F (1991) Growth hormone excess and galactorrhoea without acromegalic features. Case reports. BJOG 98(1):92–97CrossRefGoogle Scholar
  30. 30.
    Kovacs K, Lloyd R, Horvath E, Asa SL, Stefaneanu L, Killinger DW, Smyth HS (1989) Silent somatotroph adenomas of the human pituitary. A morphologic study of three cases including immunocytochemistry, electron microscopy, in vitro examination, and in situ hybridization. Am J Pathol 134(2):345–353PubMedPubMedCentralGoogle Scholar
  31. 31.
    Matsuno A, Ogino Y, Itoh J, Osamura RY, Nagashima T (2000) Detection of a silent pituitary somatotroph adenoma in a patient with amenorrhea and/or galactorrhea: paradoxical response of GH in TRH or GnRH provocation test. Endocr J 47(Suppl March):S105–S109CrossRefPubMedGoogle Scholar
  32. 32.
    Mete O, Gomez-Hernandez K, Kucharczyk W, Ridout R, Zadeh G, Gentili F, Ezzat S, Asa SL (2016) Silent subtype 3 pituitary adenomas are not always silent and represent poorly differentiated monomorphous plurihormonal Pit-1 lineage adenomas. Mod Pathol 29(2):131–142CrossRefPubMedGoogle Scholar
  33. 33.
    Villa C, Lagonigro MS, Magri F, Koziak M, Jaffrain-Rea ML, Brauner R, Bouligand J, Junier MP, Di Rocco F, Sainte-Rose C, Beckers A, Roux FX, Daly AF, Chiovato L (2011) Hyperplasia-adenoma sequence in pituitary tumorigenesis related to aryl hydrocarbon receptor interacting protein gene mutation. Endocr Relat Cancer 18(3):347–356CrossRefPubMedGoogle Scholar
  34. 34.
    Yamada S, Ohyama K, Taguchi M, Takeshita A, Morita K, Takano K, Sano T (2007) A study of the correlation between morphological findings and biological activities in clinically nonfunctioning pituitary adenomas. Neurosurgery 61(3):580–584CrossRefPubMedGoogle Scholar
  35. 35.
    Nishioka H, Inoshita N, Mete O, Asa SL, Hayashi K, Takeshita A, Fukuhara N, Yamaguchi-Okada M, Takeuchi Y, Yamada S (2015) The complementary role of transcription factors in the accurate diagnosis of clinically nonfunctioning pituitary adenomas. Endocr Pathol 26(4):349–355CrossRefPubMedGoogle Scholar
  36. 36.
    Klibanski A, Zervas NT, Kovacs K, Ridgway EC (1987) Clinically silent hypersecretion of growth hormone in patients with pituitary tumors. J Neurosurg 66(6):806–811CrossRefPubMedGoogle Scholar
  37. 37.
    Yamada S, Sano T, Stefaneanu L, Kovacs K, Aiba T, Sawano S, Shishiba Y (1993) Endocrine and morphological study of a clinically silent somatotroph adenoma of the human pituitary. J Clin Endocrinol Metab 76(2):352–356PubMedGoogle Scholar
  38. 38.
    Sakharova AA, Dimaraki EV, Chandler WF, Barkan AL (2005) Clinically silent somatotropinomas may be biochemically active. J Clin Endocrinol Metab 90(4):2117–2121CrossRefPubMedGoogle Scholar
  39. 39.
    Kontogeorgos G (2005) Classification and pathology of pituitary tumors. Endocrine 28(1):27–35CrossRefPubMedGoogle Scholar
  40. 40.
    Syro LV, Rotondo F, Serna CA, Ortiz LD, Kovacs K (2017) Pathology of GH-producing pituitary adenomas and GH cell hyperplasia of the pituitary. Pituitary 20(1):84–92CrossRefPubMedGoogle Scholar
  41. 41.
    Sidhaye A, Burger PMD, Rigamonti D, Salvatori R (2005) Giant Somatotrophinoma without acromegalic features: more “quiet” than “silent”: case report. Neurosurgery 56(5):E1154PubMedGoogle Scholar
  42. 42.
    Fleseriu M, Bodach ME, Tumialan LM, Bonert V, Oyesiku NM, Patil CG, Litvack Z, Aghi MK, Zada G (2016) Congress of neurological surgeons systematic review and evidence-based guideline for pretreatment endocrine evaluation of patients with nonfunctioning pituitary adenomas. Neurosurgery 79(4):E527–E529CrossRefPubMedGoogle Scholar
  43. 43.
    Schilbach K, Strasburger CJ, Bidlingmaier M (2017) Biochemical investigations in diagnosis and follow up of acromegaly. Pituitary 20(1):33–45CrossRefPubMedGoogle Scholar
  44. 44.
    Veldhuis JD, Roelfsema F, Keenan DM, Pincus S (2011) Gender, age, body mass index, and IGF-I individually and jointly determine distinct GH dynamics: analyses in one hundred healthy adults. J Clin Endocrinol Metab 96(1):115–121CrossRefPubMedGoogle Scholar
  45. 45.
    Katznelson L, Laws ER Jr, Melmed S, Molitch ME, Murad MH, Utz A, Wass JA, Endocrine S (2014) Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 99(11):3933–3951CrossRefPubMedGoogle Scholar
  46. 46.
    Fleseriu M, Hashim IA, Karavitaki N, Melmed S, Murad MH, Salvatori R, Samuels MH (2016) Hormonal Replacement in hypopituitarism in adults: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 101(11):3888–3921CrossRefPubMedGoogle Scholar
  47. 47.
    Mavromati M, Kuhn E, Agostini H, Brailly-Tabard S, Massart C, Piketty ML, Arnoux A, Young J, Souberbielle JC, Chanson P (2017) Classification of patients With GH disorders may vary according to the IGF-I assay. J Clin Endocrinol Metab 102(8):2844–2852CrossRefPubMedGoogle Scholar
  48. 48.
    Freda PU (2009) Monitoring of acromegaly: what should be performed when GH and IGF-1 levels are discrepant? Clin Endocrinol (Oxford) 71(2):166–170CrossRefGoogle Scholar
  49. 49.
    Faje AT, Barkan AL (2010) Basal, but not pulsatile, growth hormone secretion determines the ambient circulating levels of insulin-like growth factor-I. J Clin Endocrinol Metab 95(5):2486–2491CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Butz LB, Sullivan SE, Chandler WF, Barkan AL (2016) “Micromegaly”: an update on the prevalence of acromegaly with apparently normal GH secretion in the modern era. Pituitary 19(6):547–551CrossRefPubMedGoogle Scholar
  51. 51.
    Ribeiro-Oliveira A Jr, Faje AT, Barkan AL (2011) Limited utility of oral glucose tolerance test in biochemically active acromegaly. Eur J Endocrinol 164(1):17–22CrossRefPubMedGoogle Scholar
  52. 52.
    Lania AG, Ferrero S, Pivonello R, Mantovani G, Peverelli E, Di Sarno A, Beck-Peccoz P, Spada A, Colao A (2010) Evolution of an aggressive prolactinoma into a growth hormone secreting pituitary tumor coincident with GNAS gene mutation. J Clin Endocrinol Metab 95(1):13–17CrossRefPubMedGoogle Scholar
  53. 53.
    Andersen M, Hagen C, Frystyk J, Schroeder HD, Hagen C (2003) Development of acromegaly in patients with prolactinomas. Eur J Endocrinol 149(1):17–22CrossRefPubMedGoogle Scholar
  54. 54.
    Manuylova E, Calvi LM, Hastings C, Vates GE, Johnson MD, Cave WT Jr, Shafiq I (2016) Late presentation of acromegaly in medically controlled prolactinoma patients. Endocrinol Diabetes Metab Case Rep.  https://doi.org/10.1530/EDM-16-0069 PubMedPubMedCentralGoogle Scholar
  55. 55.
    Matsuno A, Sanno N, Tahara S, Teramoto A, Osamura RY, Wada H, Murakami M, Tanaka H, Nagashima T (1999) Silent somatotroph adenoma, detected by catalyzed signal amplification and non-radioisotopic in situ hybridization. Endocr J 46(Suppl):S81–S84CrossRefPubMedGoogle Scholar
  56. 56.
    Birzniece V, Sata A, Sutanto S, Ho KKY (2010) Paracrine regulation of growth hormone secretion by estrogen in women. J Clin Endocrinol Metab 95(8):3771–3776CrossRefPubMedGoogle Scholar
  57. 57.
    Ben-Jonathan N, Liby K, McFarland M, Zinger M (2002) Prolactin as an autocrine/paracrine growth factor in human cancer. Trends Endocrinol Metab 13(6):245–250CrossRefPubMedGoogle Scholar
  58. 58.
    Pagesy P, Li JY, Kujas M, Peillon F, Delalande O, Visot A, Derome P (1991) Apparently silent somatotroph adenomas. Pathol Res Pract 187(8):950–956CrossRefPubMedGoogle Scholar
  59. 59.
    Hallengren E, Almgren P, Svensson M, Gallo W, Engstrom G, Persson M, Melander O (2017) Genetic determinants of growth hormone and GH-related phenotypes. BMC Genom 18(1):822CrossRefGoogle Scholar
  60. 60.
    Leung K-C, Johannsson G, Leong GM, Ho KKY (2004) Estrogen regulation of growth hormone action. Endocr Rev 25(5):693–721CrossRefPubMedGoogle Scholar
  61. 61.
    Duarte FH, Jallad RS, Bronstein MD (2016) Estrogens and selective estrogen receptor modulators in acromegaly. Endocrine 54(2):306–314CrossRefPubMedGoogle Scholar
  62. 62.
    Brzana JA, Yedinak CG, Delashaw JB, Gultelkin HS, Cook D, Fleseriu M (2012) Discordant growth hormone and IGF-1 levels post pituitary surgery in patients with acromegaly naive to medical therapy and radiation: what to follow, GH or IGF-1 values? Pituitary 15(4):562–570CrossRefPubMedGoogle Scholar
  63. 63.
    Bianchi A, Giustina A, Cimino V, Pola R, Angelini F, Pontecorvi A, De Marinis L (2009) Influence of growth hormone receptor d3 and full-length isoforms on biochemical treatment outcomes in acromegaly. J Clin Endocrinol Metab 94(6):2015–2022CrossRefPubMedGoogle Scholar
  64. 64.
    Boguszewski CL, Barbosa EJL, Svensson PA, Johannsson G, Glad CAM (2017) MECHANISMS IN ENDOCRINOLOGY: Clinical and pharmacogenetic aspects of the growth hormone receptor polymorphism. Eur J Endocrinol 177(6):R309–R321CrossRefGoogle Scholar
  65. 65.
    Abe T, Taniyama M, Xu B, Ozawa H, Kawamura N, Shimazu M, Sasaki K, Izumiyama H, Kushima M, Kuwazawa J, Sano T, Matsumoto K (2001) Silent mixed corticotroph and somatotroph macroadenomas presenting with pituitary apoplexy. Acta Neuropathol 102(5):435–440PubMedGoogle Scholar
  66. 66.
    Chinezu L, Jouanneau E, Vasiljevic A, Trouillas J, Raverot G (2013) Clinical case: Silent GH pituitary tumor: diagnostic and therapeutic challenges. Les adénomes hypophysaires somatotropes silencieux: défis thérapeutiques et diagnostiques, vol 74. Elsevier Masson, Toronto, pp. 491–495 (French)Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2017

Authors and Affiliations

  1. 1.Department of EndocrinologyCentre hospitalier universitaire de SherbrookeSherbrookeCanada
  2. 2.Department of PathologyOregon Health & Science UniversityPortlandUSA
  3. 3.Department of Neurological SurgeryOregon Health & Science UniversityPortlandUSA
  4. 4.Department of MedicineOregon Health & Science UniversityPortlandUSA
  5. 5.Northwest Pituitary CenterOregon Health & Science UniversityPortlandUSA

Personalised recommendations